Promoting the pharmaceuticalization of guideline therapy and defining a new paradigm in Immune Surgery.
Immune Oncology Systems, Inc. (IOS) and Jinan Jiazuo Pharmaceutical Technology Co., Ltd. are the core R&D platforms of Baofa Medical Group.
We adhere to a "China-Us dual-core drive" strategy and are dedicated to developing and commercializing breakthrough tumor treatment options centered on "Cancer Immune Surgery" worldwide.
With an endogenous "R&D - clinical - industry" integrated ecosystem, we ensure a full internal cycle from clinical need discovery to rapid product validation.
Chinese Patent of Slow Release Depot Therapy
U.S. Patent of Slow Release Depot Therapy
Australian Patent of Slow Release Depot Therapy
US patent of organ targeted therapy
Invention patent: a multifunctional therapy assisted robot
Utility model patent: a temperature controller for hyperthermia equipment
Utility model patent: a puncture instrument clamping guide device
Utility model patent: a drug mixing device for auxiliary therapy robots
Utility model patent: an ozone gas injection therapy device
Utility model patent: a needle insertion mechanism for percutaneous puncture
Founder
Inventor of Immunosustained-release library therapy (UMPIC) and foreign academician of the Russian Academy of Natural Sciences. Postdoctoral research at UCSD and Salk Institute. Recipient of "Outstanding Entrepreneurship Award for Overseas Chinese Professionals".
Chief Scientist
2006 Nobel Prize winner in Physiology or Medicine for "Discovery of RNA interference (RNAi)". Distinguished Professor at UMass Medical School and former co-director of the RNA Therapy Institute.
Scientific Advisor
Current Secretary General and former President of the American Pancreatic Association (APA). Internationally recognized authority on pancreatic disease research with over 130 SCI academic papers.